Kala Pharmaceuticals (NASDAQ:KALA – Get Rating) had its price objective cut by analysts at HC Wainwright from $4.00 to $2.50 in a research note issued on Monday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Separately, Wedbush dropped their price objective on shares of Kala Pharmaceuticals from $6.00 to $3.00 and […]